ACAD ACADIA PHARMACEUTICALS INC
FY2025 10-K
ACADIA PHARMACEUTICALS INC (ACAD) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: biopharmaceutical focus on neurological and rare diseases with $1.07B net sales from NUPLAZID and DAYBUE in 2025, up from $958M in 2024
- • New product launch: DAYBUE STIX powder formulation introduced in Q1 2026 for Rett syndrome, offering dosing flexibility and improved patient experience
Management Discussion & Analysis
- • Revenue $1,071.5M in 2025 vs $957.8M in 2024, driven by NUPLAZID and DAYBUE sales, up $113.7M YoY
- • Operating loss driven by R&D expenses $328.8M in 2025 vs $303.2M in 2024; gross-to-net adjustments reduced net sales by $20.1M from Medicare rebate revision
Risk Factors
- • Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance
- • New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy
Financial SummaryXBRL
Revenue
$1.1B
Net Income
$391M
Operating Margin
9.8%
Net Margin
36.5%
ROE
31.9%
Total Assets
$1.6B
EPS (Diluted)
$2.30
Operating Cash Flow
$110M
Source: XBRL data from ACADIA PHARMACEUTICALS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ACADIA PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.